Bio-Thera: BAT1308 injection received notification of clinical trial

Bio-Thera announced that on May 26, 2020, the company received the “Clinical Trial Notice” issued by the State Drug Administration regarding the company’s drug BAT1308 injection.

Bio-Thera announced that on May 26, 2020, the company received the “Clinical Trial Notice” issued by the State Drug Administration regarding the company’s drug BAT1308 injection.

BAT 1308 injection is a monoclonal antibody drug independently developed by Bio-Thera.

It can combine with PD-1 on the surface of T cells to release the inhibitory effect of PD-1 pathway on T cells, thereby restoring and improving the immune killer function of T cells and inhibiting tumor growth.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/28/bio-thera-bat1308-injection-received-notification-of-clinical-trial/.

Leave a Reply

Your email address will not be published. Required fields are marked *